Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunctive Docosahexaenoic Acid in Residual Symptoms of Depression and Anxiety.

Journal of clinical psychopharmacology·2023
Same author

Letters to the Editor: Author reply to Letters to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia?'

The Australian and New Zealand journal of psychiatry·2023
Same author

A challenge to the dopamine orthodoxy in schizophrenia?

The Australian and New Zealand journal of psychiatry·2023
Same author

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.

CNS spectrums·2022
Same author

Diagnostic agreement and concordance between consultation-liaison psychiatry and non-psychiatric (medical and surgical) doctors: changes within junior doctor's terms.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists·2022
Same author

Desvenlafaxine in the treatment of major depression: an updated overview.

Expert opinion on pharmacotherapy·2021

Related Experiment Video

Updated: Jul 17, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Emerging treatments for major depression.

Trevor R Norman1, Graham D Burrows

  • 1University of Melbourne, Department of Psychiatry, Austin Hospital, Heidelberg 3084, Victoria, Australia. trevorrn@unimelb.edu.au

Expert Review of Neurotherapeutics
|February 9, 2007
PubMed
Summary

New antidepressant drugs aim to improve efficacy and safety beyond current medications. Research explores novel compounds targeting various biological pathways, with some showing promise in clinical and preclinical studies for depression treatment.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Jul 17, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Area of Science:

  • Pharmacology and Psychiatry
  • Neuroscience and Drug Development

Background:

  • Established antidepressant medications, while effective, possess notable limitations.
  • There is a continuous need for novel antidepressant agents with improved efficacy, tolerability, and safety profiles.
  • Current research focuses on developing new molecules to address the shortcomings of existing treatments.

Purpose of the Study:

  • To review emerging compounds with potential antidepressant properties.
  • To assess the developmental stage and preclinical/clinical evidence for these novel agents.
  • To highlight diverse pharmacological approaches beyond traditional monoamine-based mechanisms.

Main Methods:

  • Review of compounds that have undergone clinical trials (e.g., agomelatine, duloxetine).
  • Examination of preclinical data from validated animal models for compounds yet to enter clinical trials.
  • Analysis of novel targets including cortisol secretion pathways, substance P, vasopressin, neuropeptide Y, and glutamatergic transmission.

Main Results:

  • Agomelatine and duloxetine demonstrate antidepressant efficacy in clinical trials.
  • Cortisol-blocking agents (synthesis inhibitors, CRF, and glucocorticoid receptor antagonists) show promise.
  • Neuropeptide antagonists (substance P, vasopressin, neuropeptide Y) represent alternative mechanisms, with mixed developmental outcomes.
  • Glutamatergic transmission modulators show potential based on animal models, awaiting clinical evaluation.

Conclusions:

  • Several novel compounds and therapeutic strategies are under investigation for antidepressant potential.
  • Future assessment of these agents requires long-term outcome data and post-marketing surveillance.
  • The ultimate superiority of new antidepressants over existing ones remains to be determined.